Fortea, Juan http://orcid.org/0000-0002-1340-638X
Pegueroles, Jordi http://orcid.org/0000-0002-3554-2446
Alcolea, Daniel http://orcid.org/0000-0002-3819-3245
Belbin, Olivia http://orcid.org/0000-0002-6109-6371
Dols-Icardo, Oriol http://orcid.org/0000-0003-2656-8748
Vaqué-Alcázar, Lídia
Videla, Laura http://orcid.org/0000-0002-9748-8465
Gispert, Juan Domingo
Suárez-Calvet, Marc http://orcid.org/0000-0002-2993-569X
Johnson, Sterling C. http://orcid.org/0000-0002-8501-545X
Sperling, Reisa http://orcid.org/0000-0003-1535-6133
Bejanin, Alexandre http://orcid.org/0000-0002-9958-0951
Lleó, Alberto http://orcid.org/0000-0002-2568-5478
Montal, Víctor http://orcid.org/0000-0002-5714-9282
Article History
Received: 3 November 2023
Accepted: 19 March 2024
First Online: 6 May 2024
Change Date: 17 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-03127-y
Competing interests
: S.C.J. has served at scientific advisory boards for ALZPath, Enigma and Roche Diagnostics. M.S.-C. has given lectures in symposia sponsored by Almirall, Eli Lilly, Novo Nordisk, Roche Diagnostics and Roche Farma, received consultancy fees (paid to the institution) from Roche Diagnostics and served on advisory boards of Roche Diagnostics and Grifols. He was granted a project and is a site investigator of a clinical trial (funded to the institution) by Roche Diagnostics. In-kind support for research (to the institution) was received from ADx Neurosciences, Alamar Biosciences, Avid Radiopharmaceuticals, Eli Lilly, Fujirebio, Janssen Research & Development and Roche Diagnostics. J.D.G. has served as consultant for Roche Diagnostics, receives research funding from Hoffmann–La Roche, Roche Diagnostics and GE Healthcare, has given lectures in symposia sponsored by Biogen, Philips Nederlands, Esteve and Life Molecular Imaging and serves on an advisory board for Prothena Biosciences. R.S. has received personal consulting fees from Abbvie, AC Immune, Acumen, Alector, Bristol Myers Squibb, Janssen, Genentech, Ionis and Vaxxinity outside the submitted work. O.B. reported receiving personal fees from Adx NeuroSciences outside the submitted work. D.A. reported receiving personal fees for advisory board services and/or speaker honoraria from Fujirebio-Europe, Roche, Nutricia, Krka Farmacéutica and Esteve, outside the submitted work. A.L. has served as a consultant or on advisory boards for Almirall, Fujirebio-Europe, Grifols, Eisai, Lilly, Novartis, Roche, Biogen and Nutricia, outside the submitted work. J.F. reported receiving personal fees for service on the advisory boards, adjudication committees or speaker honoraria from AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Lundbeck, Perha, Roche and outside the submitted work. O.B., D.A., A.L. and J.F. report holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to Adx, EPI8382175.0). The remaining authors declare no competing interests.